Noven Pharmaceuticals Inc receives final FDA approval for Stavzor

Thu. July 31, 2008; Posted: 08:54 AM

Jul 31, 2008 (M2 EQUITYBITES via COMTEX) -- NOVN | Quote | Chart | News | PowerRating -- Noven Pharmaceuticals Inc (NASDAQ:NOVN), a speciality pharmaceutical company, reported on 30 July the receipt of final approval from the US Food and Drug Administration (FDA) for Stavzor (valproic acid delayed release capsules) in 125mg, 250mg and 500mg strengths for the treatment of bipolar disorder, seizures and migraine headaches.

The company's speciality pharmaceutical subsidiary, Noven Therapeutics LLC, will market and sell Stavzor. The product is anticipated to be launched in pharmacies in the second half of August. Reportedly, Stavzor soft gel capsules are small (up to 40% smaller than Depakote and Depakote ER tablets at the 500 mg dosage strength) and easy to swallow, with an advanced enteric technology designed to reduce reflux and gastric irritability.

Comments on this story may be sent to admin@m2.com

For full details on Noven Pharmaceuticals (NOVN) click here. Noven Pharmaceuticals (NOVN) has Short Term PowerRatings of 3. Details on Noven Pharmaceuticals (NOVN) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News | Stock Index

Archives

Feedback

Email Article Link

Close X

RELATED SITES

Please call 1-213-955-5858 ext. 1

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.